The latest move in BeOne Medicines (NasdaqGS:ONC) has been shaped by the U.S. FDA granting accelerated approval to BEQALZI, or sonrotoclax, for adults with relapsed or refractory mantle cell lymphoma after at least two prior therapies.

Recent approvals and clinical partnerships have come alongside a 7 day share price return of 5.79%, while the 90 day share price return is down 14.33% and the 1 year total shareholder return is 28.51%. This suggests that shorter term momentum has cooled compared with longer term gains.

If oncology catalysts like BEQALZI interest you, it may be worth widening your search to other cancer focused opportunities through the Simply Wall St screener for 34 healthcare AI stocks

With BeOne Medicines trading at US$310.25 and sitting at an estimated 65% discount to one intrinsic value estimate, and about 33% below one analyst target, is the recent oncology progress a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 24.6% Undervalued

BeOne Medicines most followed narrative points to a fair value of $411.51 per share versus the latest close at $310.25, framing today’s oncology headlines against a higher long term valuation anchor.

Value inflection points are approaching as multiple pivotal trial readouts and global filings (for sonrotoclax, BTK CDAC, and solid tumor assets) are expected by 2026, lining up with increased adoption and reimbursement potential driven by broader healthcare investment and potential upside to future earnings as breakthrough therapies achieve approval.

Want to see why this oncology story screens as undervalued? The narrative leans heavily on compounded earnings, fatter margins, and a future profit multiple that is far from conservative.

Result: Fair Value of $411.51 (UNDERVALUED)

However, the story could shift quickly if competition pressures Brukinsa’s pricing or if key late stage trials stumble, which would challenge today’s earnings assumptions.

Another Angle on Valuation

Analysts see BeOne Medicines trading at 67.2x P/E, which is more than double both the peer average of 31.7x and the US Biotechs average of 16.1x, and above a fair ratio of 29.9x. That rich gap points to higher valuation risk, so how comfortable are you with paying this price for the company’s growth narrative?

Next Steps

After considering both the oncology potential and the valuation risks, are you convinced the market has this story right, or could sentiment be misaligned? Act while the data is still fresh and shape your own view by reviewing the company's 4 key rewards

Looking for more investment ideas?

If this oncology story has sharpened your thinking, do not stop here. Broaden your watchlist with ideas that match your risk, income, and quality preferences.

• Target potential underpriced opportunities by scanning companies that score well on fundamentals and valuation using the 49 high quality undervalued stocks.
• Strengthen your income stream by focusing on reliable payers and sizeable yields through the 10 dividend fortresses.
• Prioritise resilience by filtering for companies with cleaner balance sheets and supportive fundamentals via the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.